| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Mar 7, 2022
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that a manuscript has been published in the...
-
Feb 24, 2022- Presented positive updated data in Phase 1/2 TakeAim Leukemia study of CA-4948 Monotherapy in Targeted Patients with Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes -
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial results for the fourth quarter ended
-
Feb 17, 2022Curis to Release Fourth Quarter 2021 Financial Results and Hold Conference Call on February 24, 2022
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its fourth...
-
Jan 20, 2022
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief...
-
Jan 7, 2022
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on January 3, 2022, the independent...